Beyond Air Inc Revenue Growth Rates (XAIR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Beyond Air Inc   (NASDAQ: XAIR)
 

XAIR's Revenue Growth by Quarter and Year

Beyond Air Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XAIR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 1.77
FY 1.77

XAIRs Annual Revenue
Beyond Air Inc 's Revenue in the fiscal year 2026 $ 7.68 millions
Beyond Air Inc 's Revenue in the fiscal year 2025 $ 3.34 millions
Beyond Air Inc 's Revenue in the fiscal year 2024 $ 0.69 millions
Beyond Air Inc 's Revenue in the fiscal year 2023 $ 0.66 millions
Beyond Air Inc 's Revenue in the fiscal year 2022 $ 0.00 millions




XAIR Revenue first quarter 2026 Y/Y Growth Comment
Beyond Air Inc achieved in the first quarter 2026, above Company average Revenue rise of 52.41% year on year, to $ 1.77 millions.

Looking into first quarter 2026 results within Medical Equipment & Supplies industry 53 other companies have achieved higher Revenue growth. While Beyond Air Inc ' s Revenue jump of 52.41% ranks overall at the positon no. 1000 in the first quarter 2026.


XAIR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter March - 66.09 % 144.68 % -28.79 %
3rd Quarter December - 64.56 % 102.56 % -
2nd Quarter September - - - -
1st Quarter June 52.41 % 70.59 % 44.68 % -
FY   - 138.98 % 61.78 % -

Financial Statements
Beyond Air Inc 's first quarter 2026 Revenue $ 1.77 millions XAIR's Income Statement
Beyond Air Inc 's first quarter 2025 Revenue $ 1.16 millions Quarterly XAIR's Income Statement


XAIR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter March - 46.92 % 45.57 % 20.51 %
3rd Quarter December - -23.53 % - 62.5 %
2nd Quarter September - 46.55 % - -48.94 %
1st Quarter June -7.43 % 0.87 % 44.68 % -28.79 %
FY (Year on Year)   - 138.98 % 61.78 % -


Back to XAIR Growth rate Comparisons >> Back to XAIR Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #54
Healthcare Sector #196
Overall #1000

Revenue Y/Y Growth Statistics
High Average Low
228.42 % 51.82 % -87.31 %
(Sep 30 2025)   (Sep 30 2020)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #54
Healthcare Sector #196
Overall #1000
Revenue Y/Y Growth Statistics
High Average Low
228.42 % 51.82 % -87.31 %
(Sep 30 2025)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Beyond Air Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
63.6 % -6.92 % -100 %
(Dec 31 2023)  


XAIR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Beyond Air Inc disclosed drop in Revenue from the fourth quarter by -7.43% to $ 1.77 millions, from $ 1.91 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 160 other companies have achieved higher Revenue quarter on quarter growth. While Beyond Air Inc 's Revenue growth quarter on quarter, overall rank is 3161.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #161
Healthcare Sector #487
Overall #3161
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #161
Healthcare Sector #487
Overall #3161
Revenue Q/Q Growth Statistics
High Average Low
63.6 % -6.92 % -100 %
(Dec 31 2023)  


XAIR's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Beyond Air Inc disclosed drop in Revenue from the fourth quarter by -7.43% to $ 1.77 millions, from $ 1.91 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 160 other companies have achieved higher Revenue quarter on quarter growth. While Beyond Air Inc 's Revenue growth quarter on quarter, overall rank is 3161.


Beyond Air Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 6.68 $ 6.06 $ 5.31 $ 4.80 $ 3.01
Y / Y Revenue Growth (TTM) 121.9 % 139.16 % 186.41 % 228.42 % 68.76 %
Year on Year Revenue Growth Overall Ranking # 290 # 3737 # 4 # 26 # 44
Seqeuential Revenue Change (TTM) 10.09 % 14.22 % 10.74 % 59.36 % 18.65 %
Seq. Revenue Growth (TTM) Overall Ranking # 1000 # 3827 # 174 # 2053 # 71


Cumulative Revenue growth Comment
Assuming the Beyond Air Inc 's fiscal year would have ended in Jun 30 2026, Beyond Air Inc would have reprted above average annual Revenue surge of 121.9% year on year, of $ 7 millions.
This marks a slow-down of the companys growth trends and from the 139.16% surge in Mar 31 2026.

In the Healthcare sector 69 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 290, from total ranking in previous quarter at 3737.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 54
Healthcare Sector # 70
Overall # 290

Revenue TTM Y/Y Growth Statistics
High Average Low
228.42 %
 51.82 %
-87.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 196
S&P 500 # 1000
Cumulative Revenue growth Comment
Assuming the Beyond Air Inc 's fiscal year would have ended in Jun 30 2026, Beyond Air Inc would have reprted above average annual Revenue surge of 121.9% year on year, of $ 7 millions.
This marks a slow-down of the companys growth trends and from the 139.16% surge in Mar 31 2026.

In the Healthcare sector 69 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 290, from total ranking in previous quarter at 3737.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 54
Healthcare Sector # 70
Overall # 290

Revenue TTM Y/Y Growth Statistics
High Average Low
228.42 %
51.82 %
-87.31 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 54
Sector # 196
S&P 500 # 1000




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XAIR's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions


About Beyond Air Inc Revenue Growth Rates (XAIR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Beyond Air Inc (CIK 1641631).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-037781
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Beyond Air Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.